Each film-coated sustained-release tablet contains Ursodeoxycholic Acid IP 450 mg.

Usibon 450 SR Tablets contain Ursodeoxycholic Acid (UDCA) in a sustained-release formulation that provides prolonged therapeutic activity for the management of cholestatic liver disorders and cholesterol gallstones. UDCA improves bile composition, reduces cholesterol saturation, promotes the dissolution of cholesterol gallstones, and supports healthy liver function by protecting hepatocytes and improving bile flow. The sustained-release formulation helps maintain consistent drug levels for effective long-term therapy.

Usibon 450 SR Tablets are indicated for the dissolution of radiolucent cholesterol gallstones and for the treatment of chronic cholestatic liver diseases, particularly Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, and cholestasis associated with cystic fibrosis.

Ursodeoxycholic Acid (UDCA) is a naturally occurring hydrophilic bile acid that converts lithogenic bile into non-lithogenic bile, thereby reducing cholesterol saturation and gradually dissolving cholesterol gallstones. It suppresses hepatic cholesterol secretion, decreases intestinal cholesterol absorption, improves bile flow, and protects hepatocytes and biliary epithelial cells from the toxic effects of hydrophobic bile acids. These actions contribute to improved liver function and reduced cholestatic injury.

The dosage of Usibon 450 SR Tablets should be calculated according to the patient's body weight and rounded to the nearest number of tablets. For the dissolution of cholesterol gallstones, the usual recommended dose is 8–10 mg/kg/day. For Primary Biliary Cholangitis, the recommended dose is 12–15 mg/kg/day, or as directed by the physician.

Usibon 450 SR Tablets are contraindicated in patients with complete biliary obstruction and in those with known hypersensitivity or intolerance to Ursodeoxycholic Acid or any component of the formulation.